New hope for kids with resistant tumors? early trial tests CUDC-907

NCT ID NCT02909777

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) with cancers that had come back or stopped responding to treatment, including solid tumors, brain tumors, and lymphoma. The main goal was to find a safe dose and check for side effects. Researchers also looked at how long the drug stayed in the body and whether it helped control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CUDC-907
What this could lead to
If it works, this could point toward a new treatment option for children with hard-to-treat cancers that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 26 participants, focused on safety and dosing. It is too small to prove effectiveness, and the drug may cause side effects or not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • Texas Children's, Baylor College of Medicine

    Houston, Texas, 77030, United States

  • University of California, San Francisco, Benioff Children's Hospital

    San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.